SŌLACE BOATS INTRODUCES THE ALL-NEW 41CT CENTER CONSOLE CATAMARAN AT THE FORT LAUDERDALE INTERNATIONAL BOAT SHOW

New 41-foot catamaran brings the SŌLACE approach to engineering, luxury, fishability and performance into an entirely new platform

EDGEWATER, Fla., Oct. 20, 2026 /PRNewswire/ -- SŌLACE Boats today announced the all-new SŌLACE 41CT, the company's first center console catamaran and the newest addition to its award-winning lineup of premium offshore boats.

Designed and manufactured at SŌLACE's facility in Edgewater, Florida, the 41CT takes the company into a new category while retaining the engineering, craftsmanship, functionality and distinctive design that define the SŌLACE brand.

At 41 feet, 3 inches in overall length with a 12-foot beam, the 41CT was designed to capitalize on the inherent advantages of a twin-hull platform while delivering an experience distinctly SŌLACE. The result is a spacious offshore platform engineered around increased stability, efficiency, range, fishability and passenger comfort.

"The 41CT represents an exciting new chapter for SŌLACE," said Stephen Dougherty of SŌLACE Boats. "We didn't want to build a catamaran simply because the market was moving in that direction. We wanted to look at the platform through the SŌLACE lens and ask how we could make it more functional, more comfortable and more enjoyable for the way our owners actually use their boats."

Designed Around the Entire Day on the Water

The 41CT combines offshore capability with a layout developed for both serious fishing and entertaining.

Expansive bow and cockpit areas provide anglers with abundant working space, while twin 60-gallon livewells and twin 187-gallon fish boxes give the boat the capacity demanded for extended offshore trips.

A 950-gallon fuel capacity supports long-range capability and opens new possibilities for owners who want to travel farther, explore more and spend longer days offshore.

At the helm, dual-row seating provides comfortable accommodations for additional passengers while underway. SŌLACE's innovative Aft Cockpit Bulkhead, first introduced on the 35CS, further transforms the experience aboard the 41CT. The opening bulkhead allows the cockpit environment to adapt to changing weather and conditions while helping isolate the helm and passenger area from cockpit and engine noise when closed.

A mezzanine seat integrated below the bulkhead provides additional aft-facing seating, cupholders and internal storage, creating another comfortable gathering point without sacrificing cockpit functionality.

Throughout the vessel, increased usable space allows the 41CT to transition naturally between fishing, cruising, entertaining and extended days with family and friends.

A New Platform, Built the SŌLACE Way

The 41CT continues SŌLACE's emphasis on vertically integrated design and manufacturing. Developed by the company's engineering team and brought to life within SŌLACE's 200,000-square-foot Edgewater manufacturing campus, the 41CT reflects the company's ability to design, tool and manufacture major components in-house.

The patented twin-hull, bisymmetrical architecture adds an entirely new dimension to the SŌLACE lineup, delivering the stability and space associated with modern performance catamarans while maintaining the finish, ergonomics and attention to detail expected from SŌLACE.

"The opportunity wasn't just to create our first catamaran," Dougherty said. "It was to create a SŌLACE catamaran. Every element had to earn its place on the boat and contribute to the experience, whether you're running offshore, fishing all day or spending the afternoon entertaining with family and friends."

See the 41CT at the 2026 Fort Lauderdale International Boat Show

The SŌLACE 41CT will be showcased during the 2026 Fort Lauderdale International Boat Show, October 28 through November 1, 2026, giving owners, dealers, media and marine industry professionals an opportunity to experience the newest SŌLACE firsthand.

About SŌLACE Boats

In a world where so much is mass-produced, predictable, and uninspired, SŌLACE Boats was created for those who expect more. The brand is built around a culture of rugged individualism, uncompromising craftsmanship, and a relentless pursuit of perfection—challenging convention and pushing beyond the ordinary in both design and performance.

Founded in 2019 by Stephen Dougherty, SŌLACE Boats draws on a multigenerational boatbuilding legacy and decades of marine innovation. Designed and manufactured in Edgewater, Florida, SŌLACE builds premium offshore boats engineered to serve a wide range of boating missions, from serious fishing and long-range cruising to luxury entertaining and family adventure.

Through advanced engineering, innovative functionality, distinctive design, and meticulous craftsmanship, SŌLACE continues to redefine what owners should expect from a modern center console and offshore boat.

Additional information about SŌLACE Boats is available at solaceboats.com. Follow our news on Facebook at Facebook.com/SOLACEboats and on Instagram at Instagram.com/SOLACEboats.

© 2026 SŌLACE Boats. All rights reserved. SŌLACE Boats, the logo and other marks are trademarks of SŌLACE Boats and/or SŌLACE Boats affiliated companies.

SOURCE Solace Boats

Share this article

The Métis National Council (MNC) is calling for an urgent nation-to-nation meeting between Canada and recognized Métis governments to discuss Bill C-39, the Building Canada Strong Act, and its implications on Métis rights and interests.

Earlier this year, MNC, together with the federally recognized Métis governments comprising its Governing Members, responded to Canada’s request for input on two related discussion papers. However, the resulting magnitude of Bill C-39, which establishes a statutory regime that will very likely facilitate adverse impacts on the constitutionally protected rights of Métis communities, most certainly requires the Government of Canada to meaningfully engage beyond a request for written submissions. Co-development of the elements that are most likely to impact Métis rights is required.

The Government of Canada has a statutory obligation to take all measures necessary, in consultation and cooperation with Indigenous peoples, to ensure new legislation, like Bill C-39, is consistent with the United Nations Declaration on the Rights of Indigenous Peoples Act, specifically outlined in section 5. The MNC and Métis governments do not believe engagement on Bill C-39 has met this threshold.

As the Métis-specific National Indigenous Organization, MNC expects meaningful engagement from Canada with Métis governments on federal initiatives affecting the Métis Nation, including Bill C-39, and can support the convening of Canada and Métis governments in constructive dialogue on this matter. Métis governments, as the governments representing Métis rights-holders, must be engaged.

As part of its research and advocacy mandate, the MNC is reviewing Bill C-39 against the input previously provided to the Government of Canada and has identified areas where Métis rights and interests may be impacted. Canada must address these concerns as the legislation proceeds through Parliament.

Métis governments are ready to work alongside Canada—as full partners—on projects of national interest, strengthening supply chains and the Canadian economy. Early partnership creates greater predictability, helps address impacts sooner, supports efficient project development, and delivers better outcomes for projects and Métis communities.

MNC looks forward to meaningful engagement with Canada as Bill C-39 proceeds, including through the parliamentary committee process. We call on Canada to undertake meaningful consultation directly with Métis governments where the legislation and its implementation may affect Métis rights and interests.

– 30 –

Since 1983, the Métis National Council has been the national and international voice of the Métis Nation within Canada. Through national research and policy development, the MNC advocates to advance the rights and interests of Métis Governments, including the implementation of the Métis Nation’s inherent right to self-determination and self-government. The MNC is committed to accountability and transparency within its operations, and to its relationships with its Governing Members and other partners.

This special edition camera will combine photography and motor racing, perfectly embodying their shared values: precision, teamwork and craftsmanship. All for the decisive moment.

LOS ANGELES, Oct. 20, 2026 /PRNewswire/ -- Two long-established brands, Leica Camera and Formula 1®, have announced their collaboration as part of a licensing partnership and will debut a special edition Leica Q3 43 Formula 1® camera at an exclusive event at the Leica Store and Gallery on Oct. 20th, 2026. The collaboration will be presented to guests by Formula 1 presenter Ariana Bravo and 2009 FIA Formula 1® Drivers' World Champion Jenson Button. A series of 26 motorsport photographs by Callo Albanese will also be on display at the event. The Italian photographer specializes in Formula 1 and motorsport photography.

Both brands have a long tradition of innovation. Driven by this spirit, they created a camera that enables exceptionally authentic photography and translates the fascination sparked by motorsport into a handcrafted design. This is achieved through features including a wireless charging handgrip with a carbon fiber shell, a soft-release button with a carbon inlay and red rim, and a matching thumb rest. Its details also include a non-slip Microvelour covering modelled on a racing steering wheel, an F1 logo on the top plate and lens cap, and a rope strap included in the set that is in keeping with the carbon fiber components and bears both brands' logos. This is craftsmanship from Leica, inspired by the world of Formula 1.

A Partner When It Matters Most: The Decisive Moment

Formula 1 races take place in an environment exerting the highest technical demands. Performance does not stem from a single element, but from the precise interplay of components and team members. All of these factors are united by a commitment to keep fine-tuning this interplay throughout an entire season. A Leica camera is created with a similar approach: the optics, sensor, design and mechanics are fine-tuned until there is nothing that stands between the photographer and their subject.

Leica Camera and Formula 1 share the same values: excellence, precision, courage and the pursuit of perfection. They are also united in the certainty that success is decided in fractions of a second and in moments that cannot be repeated. Whether it's in the cockpit or behind the camera, the responsibility for success lies with one person.

Craftsmanship with a Racing Spirit

The visible fiber structure on this camera edition is made from genuine carbon. This material is not traditionally used in Leica cameras. In motor racing, however, carbon is the defining material because it combines low weight with extreme rigidity. The carbon fiber parts for the Leica Q3 43 Formula 1® Edition have been manufactured and tested exclusively in Germany.

This creates a cohesive look from the handgrip to the thumb rest and soft-release button, and the exceptionally even finish makes the craftsmanship palpable. Light falling on the surface emphasizes the texture, giving it shifting visual depth with every movement. Carbon fiber is positioned at the key points where the camera is held and operated. The connection to motorsport is therefore not just visual, but can be felt with every shot.

The carbon fiber is complemented by a black Microvelour covering whose texture is modelled on racing steering wheels. That's also where the idea for the red accents came from: the control elements on the steering wheel are color-coded to help the driver find them quickly. The soft-release button and one of the two function buttons on the thumb rest feature the same color scheme. The set is completed by a special carrying strap featuring F1 branding and custom-designed packaging with red inlay. Every detail reflects the same level of precision demanded on the track.

The Leica Q3 43

The Leica Q3 43 provided the technical basis for this special edition. With a focal length of 43 millimeters, the APO-Summicron 43 f/2 ASPH. lens provides an angle of view that closely resembles the way the human eye naturally perceives the world. There's no need to zoom, search or miss the moment. This is particularly beneficial in the paddock and around the racetrack, where atmosphere and proximity are key to capturing the authentic essence of the scene. Thanks to Triple Resolution Technology, the BSI CMOS full-frame sensor provides the option of 60, 36 or 18 megapixels. A fast hybrid autofocus system and extensive video functions complete the package.

'Formula 1' Leica Look

The new Leica 'Formula 1' look was specifically developed for this camera to create a rendering that complements the world of motorsport. Higher contrast and richer saturation capture the atmosphere of the racetrack and paddock in the final image. This look is available exclusively on this camera via the Leica FOTOS App, and can be applied immediately while taking photos so that the effect is visible in the viewfinder, rather than only emerging during post-processing. The same app then transfers images and videos to mobile devices. Thus, the collaboration between Leica Camera and Formula 1 is not only reflected in the materials and design, but also in the visual aesthetic itself.

Availability

The Leica Q3 43 Formula 1® Edition is available starting on October 20th, 2026 at all Leica Stores, in the Leica Online Store and from specialist retailers. The retail price is $9,950. This edition is compatible with the Leica Q3 and Q3 43 photography accessories.

ABOUT LEICA CAMERA

Leica Camera AG is an international, premium manufacturer of cameras, lenses and sports optics. As part of its growth strategy, the company has expanded its portfolio to include mobile imaging (smartphones) and the manufacture of high-quality spectacle lenses and watches and is also represented in the home cinema segment with its own projectors.

Leica Camera AG, having its headquarters in Wetzlar, Germany, and a second production site in Vila Nova de Famalicão, Portugal, operates a global network of its own distribution companies with around 120 Leica Stores worldwide.

The Leica brand stands for excellence in quality, German craftsmanship and industrial design, combined with innovative technologies. An integral aspect of the brand culture is the promotion of the culture of photography, with around 30 Leica Galleries worldwide, the Leica Akademie and international awards such as the Leica Hall of Fame Award and the Leica Oskar Barnack Award (LOBA).

ABOUT FORMULA 1®

Formula 1® racing began in 1950 and is the world's most prestigious motor racing competition, as well as the world's most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: FWONA, FWONK, LLYVA, LLVYK) attributed to the Formula One Group tracking stock. The F1 logo, F1 FORMULA 1 logo, FORMULA 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.

SOURCE Leica Camera Inc.

Share this article

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

- 64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and supportive care.

- More than 10 studies have been selected to highlight the latest findings on HER2- and HER3-targeted antibody-drug conjugates (ADCs) in breast and lung cancers, advancing research on novel targets and exploring their clinical value across a range of applications.

- Hengrui Pharma continues to expand the clinical value of established products and advance its innovative pipeline, while developing new approaches for difficult-to-treat cancers such as pancreatic cancer. Hengrui puts patient needs at the center of its mission to deliver life-changing clinical value.

SHANGHAI, Oct. 20, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 will take place in Madrid, Spain, from October 23 to 27. Hengrui Pharma will present 64 research findings at the congress, including three studies accepted for Proffered Paper presentations, three for Rapid Oral presentations, 32 for Posters and 26 for e-Posters.

The ESMO Congress is a major global platform for innovative oncology drug development and scientific exchange. Hengrui Pharma has participated for 11 consecutive years since 2016, with a total of 119 research findings accepted between 2023 and 2025. This year, the number of accepted findings continues to grow, covering more than ten cancer areas, including esophageal, gastric, liver, biliary tract, pancreatic, rectal, breast, lung, cervical, prostate and nasopharyngeal cancers, as well as thymic epithelial tumors and sarcomas. The company will also host an exhibition booth for the second consecutive year, showcasing its latest progress in exploring novel targets, expanding the clinical value of its products, and developing its innovative pipeline.

Proffered Paper Presentations Highlight Novel Targets as Hengrui Pharma Advances ADC Innovation

Two independently developed ADCs from Hengrui Pharma, the HER2-targeted trastuzumab rezetecan (SHR-A1811) and the HER3-targeted ruzaltatug rezetecan (SHR-A2009), have both been selected for Proffered Paper presentations at the ESMO Congress. The studies address clinical treatment needs in breast and lung cancers, respectively. The data from these studies will be presented during the congress.

The Proffered Paper presentation on trastuzumab rezetecan will focus on progress from HORIZON-Breast06, a randomized phase 3 study in HER2-low advanced breast cancer, led by principal investigator Academician Binghe Xu of the Cancer Hospital at the Chinese Academy of Medical Sciences. One of the most representative products from Hengrui Pharma's ADC research and development platform, trastuzumab rezetecan is being developed for more than ten indications, including breast, lung, gastric, colorectal and cervical cancers. It is also among the innovative medicines with the highest number of breakthrough therapy designations in China. The study will further explore the therapeutic potential of trastuzumab rezetecan in this patient population and provide new evidence to support the expansion of its clinical applications.

The congress will also feature interim analyses from HERON-Lung01, a phase 3 trial comparing ruzaltatug rezetecan (SHR-A2009) with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small-cell lung cancer that has progressed after EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. The trial is led by principal investigator Professor Yi-Long Wu of Guangdong Provincial People's Hospital. In July 2026, following positive results from HERON-Lung01, China's National Medical Products Administration (NMPA) accepted for review the marketing application for ruzaltatug rezetecan, intended to treat adults with EGFR-mutated locally advanced or metastatic non-squamous NSCLC whose disease has progressed following EGFR-TKI therapy. In addition, a Phase III clinical trial is currently underway to evaluate ruzaltatug rezetecan in combination with EGFR TKI as a first-line treatment for patients with EGFR-mutated locally advanced or metastatic NSCLC. Outside China, ruzaltatug rezetecan has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of patients with EGFR-mutated metastatic NSCLC whose disease has progressed following treatment with a third-generation EGFR-TKI and platinum-based chemotherapy.[1] As development progresses from early exploration to larger-scale evaluation of efficacy, the latest findings on ruzaltatug rezetecan will provide new clinical evidence on the therapeutic potential of HER3-targeted ADCs in patients with non-small-cell lung cancer.

With HER2 and HER3 among its key targets, Hengrui Pharma has built an ADC development pipeline spanning multiple targets and continues to expand potential applications across cancer types and treatment settings. Its portfolio combines further development of established targets with exploration of emerging targets.

Advancing Commercialization and R&D Innovation to Expand Clinical Value

At this year's ESMO Congress, Hengrui Pharma will also present the latest research findings from its established products and innovative pipeline. Camrelizumab, a domestically developed PD-1 inhibitor with a leading number of approved indications and cancer types covered, will be featured in a Proffered Paper presentation about UNION, a phase 3 trial of neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer. Hengrui Pharma will also use the Rapid Oral session to present the latest findings on its phase 2 study into Nectin-4-targeted ADC SHR-A2102 in recurrent or metastatic cervical cancer, providing evidence to support further exploration of its clinical development potential in additional cancer types.

Alongside expanding existing treatment options, Hengrui Pharma is actively pursuing therapies for difficult-to-treat cancers such as pancreatic cancer. A combination regimen based on its independently developed KRAS G12D inhibitor HRS-4642 has been selected for a Rapid Oral presentation. This presentation will feature preliminary results from a phase 2 study of HRS-4642 plus chemotherapy, with or without adebrelimab, as perioperative therapy for KRAS G12D-mutant pancreatic cancer. HRS-4642 injection in combination with gemcitabine and nab-paclitaxel has been granted breakthrough therapy designation by the CDE of the NMPA for the first-line treatment of advanced or metastatic pancreatic cancer with a KRAS G12D mutation[2]. The research may offer new treatment possibilities for patients with pancreatic cancer and new approaches to exploring targeted therapies for KRAS mutations.

From expanding the clinical value of established products to pursuing advances in its innovative pipeline and difficult-to-treat cancers, Hengrui Pharma continues to drive clinical value through R&D innovation, opening up more treatment possibilities for patients with cancer.

Expanding Development Pathways to Bring Chinese Innovation to the World

Following its first exhibition booth in 2025, Hengrui Pharma will again host a booth at this year's ESMO Congress, providing a platform for international scientific exchange on its innovative products and related research. Representatives from Hengrui Pharma's leading R&D and innovation teams will also attend the congress to engage with oncology experts and researchers from around the world and explore how pharmaceutical innovation can benefit more patients globally.

Jo Feng, President and COO of Hengrui Pharma, said: "This year marks the eleventh time we have participated in ESMO, with 64 research presentations - a new record for Hengrui. We look forward to sharing our latest advances in innovative drug development, presenting clinical evidence demonstrating meaningful benefits for patients, and bringing more Chinese innovation to benefit patients worldwide."

Hengrui Pharma will present additional research data and updates throughout this year's ESMO Congress, further demonstrating the exploration and development of innovative Chinese medicines in global oncology.

About Hengrui Pharma

Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Hengrui Oncology

Hengrui Oncology is one of Hengrui Pharma's core strategic business areas. Following decades of development, it has established a comprehensive portfolio spanning seven major disease areas, including gastrointestinal and breast cancers, as well as oncology supportive care. As of June 2026, 14 independently developed Class 1 innovative medicines, including AiRuiKa® (Camrelizumab for Injection), HengQu® (Herombopag Olamine Tablets) and AiWeiDa® (Trastuzumab Rezetecan for Injection), had been launched in China. Supported by its global R&D system and a range of international collaborations, Hengrui Oncology is accelerating its transition from innovation in China to innovation for the world, offering more precise, accessible and high-quality treatment options for patients with cancer.

For more information, please visit: www.hengrui.

BOGOTA, Colombia, Oct. 20, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) announces that, in its report dated October 20, 2026, Fitch Ratings ("Fitch") affirmed the Company's global credit rating at BB, with a Stable Outlook, and its standalone credit profile (SACP) at'bbb-'. In addition, Fitch affirmed Ecopetrol's national long-term and short-term ratings at'AAA(col)', with a Stable Outlook, and'F1+(col)', respectively.

Fitch stated that the 'BB' global rating reflects the Company's robust financial profile and the stability of its operating metrics. In turn, Ecopetrol's standalone credit rating remains within Investment Grade (bbb-), in line with international peers in the sector.

Among the key strengths highlighted by the rating agency were Ecopetrol's liquidity profile, supported by a strong cash position, broad access to capital markets, and an adequate debt maturity structure. Fitch also estimates that the Company will not face challenges refinancing its debt obligations maturing in 2027.

The full report issued by Fitch Ratings on October 20th, 2026, which provides detailed rationale for the ratings, can be accessed below:

---------------------

Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 19,000 employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of ISA's shares, the company participates in energy transmission, the management of real-time systems (XM), and the Barranquilla–Cartagena coastal highway concession. At the international level, Ecopetrol has a stake in strategic basins in the American continent, with drilling and exploration operations in the United States (Permian basin and the Gulf of Mexico), Brazil, and Mexico, and, through ISA and its subsidiaries, Ecopetrol holds leading positions in the power transmission business in Brazil, Chile, Peru, and Bolivia, road concessions in Chile, and the telecommunications sector.

This release contains statements that may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All forward-looking statements, whether made in this release or in future filings or press releases, or orally, address matters that involve risks and uncertainties, including in respect of the Company's prospects for growth and its ongoing access to capital to fund the Company's business plan, among others. Consequently, changes in the following factors, among others, could cause actual results to differ materially from those included in the forward-looking statements: market prices of oil & gas, our exploration, and production activities, market conditions, applicable regulations, the exchange rate, the Company's competitiveness and the performance of Colombia's economy and industry, to mention a few. We do not intend and do not assume any obligation to update these forward-looking statements.

For more information, please contact:

Investor Relations Office

Email: [email protected] 

Corporate Communications (Colombia)   

Email: [email protected] 

SOURCE Ecopetrol S.A.

Share this article

FF EAI Robotics Ecosystem Inc. Announces Details for Its Listing Ceremony and Nasdaq Investor Day, Taking Place on Monday, Oct. 26, at Nasdaq's MarketSite in NYC

- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) will hold its official listing ceremony to mark the Company's name and ticker change, and first Investor Day at the Nasdaq Tower on Monday, Oct. 26.

- Subject to completion of the transaction, FFR management will provide 2026 full year guidance, share details on FFR's future strategy and business plan.

- A video recap of the event will be available at 4:30 p.m. ET on Oct. 26 at www.ff.com

LOS ANGELES, Oct. 20, 2026 /PRNewswire/ -- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) ("FFR" or the "Company"), a U.S.-based Embodied AI (EAI) robotics company, today announced details for its Nasdaq listing ceremony and first Investor Day, to be held on Oct. 26 at the Nasdaq Tower in NYC. Subject to completion of the transaction, FFR management will provide 2026 full year guidance, share further details on FFR's future strategy and business plans at this event and will be available to speak with attending investors onsite. A video recap of the event will be available beginning at 4:30 p.m. ET at www.ff.com.

FFR and FFAI recently signed definitive agreements for FFR to acquire FFAI's robotics assets and business in an all-stock transaction at an approximate $200 million valuation. FFR will issue shares at $2.246 per share, representing an approximately 50% premium to FFR's closing price on the date the agreements were signed. Upon closing, FFR will become the No. 1 U.S.-listed pure-play "Four-Core Full-Stack AI" humanoid and bionic EAI robotics ecosystem company.

Note: Event materials will be available on the FF IR website at https://investors.ff.com/events-and-presentations

About FF EAI Robotics Ecosystem Inc.

FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) (renamed from AIxCrypto Holdings, Inc. and AIXC, effective September 30, 2026) is a U.S.-based Embodied AI (EAI) robotics company that is in the process of acquiring the FF EAI Robotics business. Upon completion of the acquisition, the Company will focus on the research and development, manufacturing, commercialization, and deployment of intelligent robotic technologies, products, and industry solutions.

The Company is committed to building a "Four-Core Full-Stack" AI ecosystem covering the full lifecycle of robotics, consisting of EAI Brain & Developer Platform, EAI Devices, Industry Productivity Solutions, and EAI Data Factory. Guided by the technology and product philosophy of "One Brain, Multi-forms, Multi-capabilities," the Company aims to empower humanoid, biomimetic, and other robotic form factors through a unified EAI Brain, while continuously expanding their multi-task and multi-scenario capabilities. The ecosystem is designed to support the full robotics lifecycle, including R&D, deployment, data collection and training, operations, and commercial applications.

The FF EAI Robotics business has already achieved commercial deliveries of humanoid and biomimetic robotic products. Through its multi-form-factor robotic products, EAI technology platform, closed-loop data capabilities, and industry solutions, the business continues to advance the scaled adoption of robotics across real-world applications. The Company also operates RoboShare, a robot-sharing and services platform designed to connect robotic assets, service capabilities, customer demand, and ecosystem partners, further strengthening its robotics commercialization and service ecosystem.

For more information, visit www.ff.com.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a "Four-Core Full-Stack AI" ecosystem of EAI Brain and Developer Platform, EAI Devices, Industry Productivity Solutions and EAI Data Factory, FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future's official website: https://www.ff.com/

FFR Forward-Looking Statements

This communication, including any presentation, press release, investor materials or other document of which it forms a part (this "Communication"), contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws, regarding FF EAI Robotics Ecosystem Inc. ("FFR," the "Company," "us," "our," or "we") and our industry. All statements, whether written or oral, other than statements of historical fact, including any financial projections and any statements regarding future events, our strategy, our transition to robotics operations, our plans for RoboShare, our digital asset disposition plans, the proposed acquisition of the FF EAI Robotics business, the projections referenced in this communication, our name and ticker change, any related financing, and the anticipated benefits and timing of the foregoing, our objectives, expectations, or anticipated actions or results, are forward-looking statements. You can often identify forward-looking statements by words such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely," or "continue," or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking. These statements reflect our current expectations and projections about future events as of the date of this Communication and are necessarily based on estimates and assumptions that, while considered reasonable by management, are inherently uncertain. FFR can give no assurance that such forward-looking statements or financial projections will prove to be correct.

Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of numerous risks and uncertainties, both general and specific, including, but not limited to:

The proposed acquisition transaction and PIPE. The definitive agreements may be terminated in accordance with their terms, and the proposed transactions may not be completed on the terms described or at all; the conditions to closing, including the completion of FFAI's internal restructuring of the robotics business, the execution of key employee agreements and other customary conditions, and the parties' ability to satisfy them; the risk that the stockholder approval required under Nasdaq listing rules for the conversion of the preferred stock issued as consideration is not obtained or is delayed, and the effect of the conversion restrictions and the information statement process on the timing of conversion; the timing of the transaction and the costs of pursuing it; the issuance of a substantial number of shares as consideration and the resulting dilution to existing stockholders; the fact that the counterparty is our controlling stockholder, that it will hold a substantial majority of our outstanding shares following closing, that certain members of management serve both companies, and the conflicts of interest inherent in the transaction; the risk that the agreed valuations do not reflect the market value of our shares or of the acquired business; our dependence on the counterparty for transition, supply and support following any closing; the scope and enforceability of the non-competition and governance arrangements; the consequences of the transaction under Nasdaq listing rules, including the possibility that Nasdaq determines that the transaction requires us to satisfy initial listing requirements in connection with a business combination, change of control or change in the nature of our business; the risk that the PIPE financing, on which the transaction is not conditioned, is not completed on the anticipated terms or at all; the risk of litigation relating to the transaction; our ability to integrate and operate the acquired business; and the risk that the acquired business performs differently than anticipated.

Projections. The projections referenced in this communication were prepared by FFAI management for the FF EAI Robotics business on a standalone basis and do not reflect our existing business, transaction-related expenses or the combined company. We have not independently verified them or adopted them as guidance. They were not prepared with a view toward public disclosure or toward compliance with the published guidelines of the Securities and Exchange Commission or the American Institute of Certified Public Accountants regarding prospective financial information, and no independent registered public accounting firm has examined, compiled or performed any procedures with respect to them, and none expresses an opinion or any other form of assurance with respect to them. The projections reflect estimates and assumptions that are inherently uncertain and subject to change, including through due diligence and the review of our special committee and its financial advisor. Actual results are likely to differ, and may differ materially.

Liquidity, capital and going concern.

INSIS Brings Natural Ease into Focus Through Materials and Subtle Chinese Design

Recent coverage in ELLE Italia and Fashion Law Journal explores the Chinese womenswear brand's approach to clothing, from its signature Asymmetric Pants to the relationship between fabric, body and everyday life.

SHANGHAI, Oct. 20, 2026 /PRNewswire/ -- INSIS, the Chinese womenswear brand founded in 2015, brings together tactile materials, considered construction and subtle Chinese influences through its approach to Natural Ease. Recent features in ELLE Italia and Fashion Law Journal, alongside ELLE Italia's coverage of the brand's participation in Venice's The Third Shore, introduce international readers to the ideas and product decisions behind this approach.

For INSIS, Natural Ease begins with the experience of wearing a garment: how a fabric feels against the skin, how a cut accommodates movement, and how a piece fits into different parts of the day. These considerations connect the brand's merino wool knitwear, alpaca-blend outerwear and signature Asymmetric Pants, giving its collections a consistent emphasis on comfort, proportion and individual ways of dressing.

Natural Ease, from fabric to fit

With a core team from the textile industry and a product research and development headquarters established in Shanghai in 2019, INSIS treats material selection as an early design decision. The weight, texture and behaviour of a fabric help determine the garment's shape and construction.

Its Autumn/Winter 2026 collection includes 17.5-micron superfine Australian merino wool knitwear, yak-fibre-and-wool knits, and outerwear combining Suri alpaca with wool. Fine merino wool brings softness to pieces worn close to the skin. Yak fibre contributes warmth, while Suri alpaca adds lustre and fluidity to outerwear. The choice of yarn, blend and construction allows these qualities to take different forms.

Natural Ease also depends on the less visible work of pattern-making. Softened shoulder lines, eased armholes and seamless knitwear address how clothing rests against the body and moves with it. Selected reversible and adjustable pieces offer additional ways to wear a garment as routines and preferences change.

In its interview with INSIS, "Why 'Rooting' in Time Is Fashion's Most Radical Choice," Fashion Law Journal examines how the brand translates its ideas into decisions about materials, development, pricing and fit. The conversation gives practical context to Natural Ease, connecting the feel of a finished garment with the work involved in making it.

Asymmetric Pants and a subtle Chinese influence

The INSIS Asymmetric Pants are a signature expression of this approach. Their off-centre fronts and balanced proportions give everyday trousers a distinctive silhouette, with related designs developed in different fabrics and lengths.

Within this design language, the curved detail of the angled fly front draws inspiration from traditional Chinese architecture. That reference becomes a line in the pattern and a change in the proportions of the garment. Its origin can be understood through the construction, while the trousers remain easy to combine with a contemporary wardrobe.

The INSIS Asymmetric Wide-leg Pants feature an asymmetric wrap front, front pleats and curved side seams in brushed twill. The wider range also includes cotton-linen and wool-blend trousers, adapting the brand's interest in asymmetry to different textures and wearing needs.

This is how INSIS approaches subtle Chinese design: architectural references and an attention to material enter the structure of the clothing. A curve, a fold or an altered proportion can carry cultural meaning through a detail that feels familiar in everyday wear.

Time, Nature and Body

ELLE Italia's feature on INSIS explores the brand through Time, Nature and Body, connecting its approach to materials and construction with the everyday experience of wearing clothes. These ideas give context to Natural Ease: the feel of a fabric, the freedom to move, and the place a garment can hold in a wardrobe over time.

INSIS develops selected styles across seasons, revisiting fabrics, construction and fit. This continuity allows familiar pieces to evolve and gives wearers the opportunity to return to shapes that work for them. Natural Ease extends into this longer relationship with clothing: finding pieces that can accompany changing circumstances without demanding a new wardrobe for each one.

The brand's cultural participation brings these interests into a wider conversation. In September 2026, INSIS took part as a co-creator of The Third Shore's founding event in Venice, where cinema, science, art and craftsmanship came together. ELLE Italia's report on The Third Shore provides the context for that gathering and its exchanges across disciplines.

For INSIS, questions about materials, making and cultural knowledge have a direct connection to clothing. They inform both its product development and its expression, "Clothing, for being, for becoming"—an invitation for wearers to find their own relationship with what they wear.

About INSIS

Founded in China in 2015, INSIS is a womenswear brand with a background in textiles and a product research and development headquarters established in Shanghai in 2019. Its collections bring together Natural Ease, an emphasis on materials and subtle Chinese influences across trousers, knitwear, outerwear and everyday wardrobe pieces.

Explore INSIS clothing and its collections at insis.shop.

SOURCE INSIS

Share this article

Lovense Launches Glint, a Touch-Responsive Butt Plug That Syncs Anal Stimulation with a Partner's Thrust During Intercourse

For vibrator-loving couples, Glint offers something genuinely new: vibration driven by a partner's touch.

SINGAPORE, Oct. 20, 2026 /PRNewswire/ -- In the middle of sex, reaching for a phone to adjust a partner's toy can interrupt the very connection the toy is meant to create.

Lovense today announced Glint, a touch-responsive butt plug for couples, designed to enhance intercourse by synchronizing anal stimulation with a partner's thrust for a more intense, connected dual penetration experience. Its external base responds to a partner's thrust as well as to touch, translating that contact into responsive anal stimulation in real time.

Glint allows couples to shape the experience through the movement and touch they are already sharing—not through a phone screen. Glint is not simply removing the phone from the experience. It changes what controls the experience: physical touch, contact and movement become the real-time input.

The numbers behind the pause

In a nationally representative U.S. study published by researchers at Indiana University[1], 43.8% of heterosexual men reported having used a vibrator. Among male vibrator users, approximately 94% had used one during partnered sexual activity and 82% during intercourse. The research suggests that vibrators are already part of partnered sex. The next question is not whether couples use them, but how physical interaction can become part of the control.

Grand View Research projects the global sextech market to reach USD 107.85 billion by 2030[2,3], growing at 16.77% annually—nearly twice the projected growth rate of the sex toys market, which is expected to reach USD 62.7 billion at a CAGR of 8.69%. Many of these devices now connect to apps and to other devices.

What makes Glint different

Glint is worn anally. The base stays outside the body and carries a touch sensor that reads how much skin is on it, at what angle and for how long, then moves the vibration across five intensity levels. A light touch can produce a lighter response, while broader or firmer contact can produce a stronger response, depending on the user's sensitivity setting.

Users set their sensitivity and choose from three response modes in the Lovense Remote app:

- Pulse, for rhythmic touch-based feedback;

- Sustain, for continuous vibration while contact continues;

- Crescendo, for vibration that builds as contact is maintained.

Glint is 0.84 inches (21.5 mm) across and weighs 55 grams. The small size keeps it comfortable to wear and approachable for people new to anal play. Its compact anal form factor is designed to stay out of the way during intercourse. It runs up to 7,500 vibrations per minute, lasts 95 to 178 minutes on a charge depending on level, charges in about an hour and is IPX7 waterproof. Through Toy Sync, its base can also control other Lovense devices.

Three ways couples will use it

Thrust-synced intercourse. During intercourse, each thrust against the external base is synchronized with anal stimulation in real time. The stimulation follows the couple's rhythm rather than a preset pattern. With Glint in place, dual penetration feels fuller and more intense.

Touch-led foreplay. One partner wears Glint while the other explores the external base with a fingertip or hand. The wearer feels the response change as contact changes. The wearer can choose whether Touch Response is active and set the sensitivity before play begins.

Two toys, one movement. One partner wears Glint while the other wears a compatible Lovense device, such as Edge 2, Lush 4 or Gush 2 Motion. When the toys are paired through Toy Sync, physical contact with Glint can trigger responsive feedback in both devices, allowing the couple's movement to shape the shared experience in real time. For example, one partner may wear Glint while the other wears Edge 2, Lovense's prostate massager, allowing both partners to feel stimulation shaped by the same thrust. Either partner can wear Glint. The wearer remains in control, while the couple creates the rhythm together.

For couples in different locations, Lovense Remote continues to provide long-distance control.

For in-person use, Glint includes Touch Records, which is optional and turned off by default. If enabled, Touch Records lets users review selected interaction data after a session.

The oldest interface

"The simplest thing two people do during sex is touch each other," said Dan Liu, CEO of Lovense. "With Glint, we wanted to explore what happens when touch becomes a new control layer between two people—so the couple can stay inside the interaction rather than reaching for a screen."

Since 2010, Lovense has built an ecosystem that turns signals from apps, games and live streams into feedback on connected devices. Glint adds physical touch and movement as another way for signals to reach the body. The app is still there for setup and for partners in different cities; during sex, the couple can leave it on the nightstand.

Availability

Glint launches worldwide on October 20, 2026 and will be available at lovense.com.

About Lovense

Lovense is a connected intimacy technology company founded in 2010. Its ecosystem combines smart intimate devices, the Lovense Remote app, creator and live-streaming tools, platform integrations and developer APIs to help individuals and couples create more connected experiences across distance, content and everyday intimacy.

SOURCE Lovense

Share this article

Beginning with AMGA in March and wrapping up with AHIP in June, healthcare leaders are grappling with game-changing, industry-shifting challenges, inside and out. As your trusted data activation partner, we at Lightbeam have compiled our take on the top takeaways so far. More to come.

I. The Real Cost of Staffing Challenges and Burnout

Staff shortages and caregiver burnout continue to concern healthcare industry leaders. According to the recently published KLAS Arch Collaborative report, burnout rates among physicians and nurses are declining slightly, but they remain above pre-pandemic levels, with staffing shortages emerging as a primary factor. Based on KLAS data collected from more than 20,000 physicians and 32,000 nurses between January 2022 and August 2023, the report also found that clinicians want improved staffing and better alignment from leadership, greater electronic health record (EHR) efficiency, and better pay.

Meanwhile, those who report they are starting to feel burned out cite concerns about efficiency, while those who are completely burned out cite concerns related to their organizational operations more broadly. Moreover, the severity of clinician burnout and the likelihood of their leaving the organization are strongly correlated.

Top factors contributing to clinician burnout:

Burnout is consistent across work environments, but it differs by organization type. The report concludes that physicians and nurses working in community health systems are the most affected, likely because these organizations experience higher turnover rates that result in increased workloads and less support.

Besides staffing shortages, lack of role-based EHRs personalization and the need for EHR education are key factors. Too many repetitive tasks and an abundance of errors also contribute to the burnout. Given this sobering reality, digital transformation and smart AI integration have been top priority topics during this conference season. As agentic AI/AI agents replace GenAI moving forward, healthcare organizations will need a portfolio management approach to AI to manage effective integration.

II. The Status of Healthcare AI Adoption: What’s Next?

AI spending in healthcare and life sciences is projected to grow from $11.6 billion in 2024 to $19 billion by 2027, with a five-year compound annual growth rate (CAGR) of 16.6%, per Gartner. That is astronomical spend that demands a strategic understanding of organization priorities and the tools that will enable them.

Except for their interest in a few ambient listening use cases, most CIOs, CTOs, CDOs, and CAOs state that AI offerings from eager AI startups are “solutions looking for problems” with little relevance for their most pressing challenges. Healthcare providers are frustrated as they attempt to “cut through the noise” and find relevant, purposeful use cases for AI in healthcare that deliver value and ROI, especially with all the disproportionate hype around GenAI and LLMs.

They are disappointed because they have not seen the value and results associated with these GenAI efforts which have not proven its efficacy except for ambient clinical intelligence (ACI) or ambient listening. As a matter of fact, only 43% of all healthcare organizations who have invested in AI have seen any or significant ROI from their investment.

III. Increasing Interest in and Adoption of Agentic AI and AI Agents

Given the diminishing returns from Gen AI/LLMs, agentic AI/AI agents are becoming increasingly attractive and relevant. We are approaching an era where AI will be synonymous with agentic AI/AI agents and hybrid and multimodal AI as part of an integrated approach. This year, venture firms and the GenAI startups they have spawned will be rapidly moving their investments into AI agents to reposition their brands as agentic AI innovators vs. GenAI integrators. Here is a summary of the differences:

Table 1. Key Differences (Attributes/Features) between Agentic AI/AI Agents and Gen AI/LLMs and Primary Use Cases in Healthcare.

As AI deployment matures, a hybrid or multimodal portfolio management will most likely deliver the greatest payback, value, and ROI that have eluded early GenAI adopters. Stay tuned and follow Lightbeam as we expand our advanced, purpose-built platform with the power of AI—customized to alleviate administrative burden and transform patient outcomes.

As always, I welcome your comments and feedback via email at ade@lightbeamstag.wpengine.com.

Read more about Lightbeam AI, or request a demo.

#HIMSS25 #AIinHealthcare #MachineLearning #NLP #NLG #AIagents #AgenticAI #AIPaaS #AIaaS #MedicalRobotics #EnterpriseSaaSDisruption #LightbeamAI

Here are more reflections on the evolution of AI and its projected impact on the enterprise SaaS industry over the next five years, informed by my observations and anecdotal data gathered from my convening colleagues.

I. From Generative AI/LLMs in 2024 to Agentic AI in 2025

2024 was the year of GenAI/LLMs, highlighting ambient clinical intelligence or ambient listening. Microsoft, a Lightbeam partner, has made massive investments in AI, including Chat GPT and Copilot embedded in all Microsoft Office products, propelling AI expectations across the healthcare industry.

Given the expanding GenAI interest, investments, and hype over the last two years, I have not been surprised about the proliferation of new ambient listening solutions and apps at the various conferences this year. In the coming years, I predict that ambient listening will evolve from a monetized point solution to an embedded feature in the agentic AI-powered electronic health records (EHRs) of tomorrow.

Lightbeam AI is innovating to deliver ambient listening capabilities within its care management solution, which will capture and convert from speech to text and summarize patient notes for a care/case manager or care coordinator. This will not only improve their productivity but also alleviate administrative task fatigue and burnout. Details to come, so stay tuned.

II. AI, Healthcare, and the Enterprise SaaS Industry

Here is the roadmap we have developed at Lightbeam to track the expansion of AI in healthcare and how that will impact the enterprise SaaS industry.

A framework for the evolution of AI in Healthcare and its impact on the Enterprise SaaS industry.

The y-axis quantifies the anticipated value, ROI, and payback on AI strategy, investments, and resources in healthcare, while the x-axis is a temporal continuum tracking the evolution of AI and its impact. The graph tracks the developmental process from augmentation of current SaaS capabilities to autonomous AI, which refers to AI systems capable of performing tasks and making decisions independently without human intervention or oversight.

On the way to autonomous AI, we are witnessing AI prescriptive actioning (enabled by a combo of ML/ NLP/NLG, and LLMs vs. descriptive and predictive analytics) with a portfolio of prescriptive actions recommended for intervention and decision making. The next step in this evolution is AI automation through AI agents enabled by carefully curated LLMs or SLMs (Small Language Models) that will automate steps in a process, workflows, or eventually, entire processes, which will pave the way for autonomous AI.

III. The Advent of AI Platform-as-a-Service (AI PaaS) and DIY tradeoffs in 2025-27

AI Platform-as-a-Service (AI PaaS) solutions are proliferating from a variety of major vendors. Enterprise SaaS vendors or healthcare organizations seeking to augment their AI capabilities can now make strategic choices regarding building their own AI solutions or buying/renting an AI PaaS solution from these vendors to accelerate time-to-market at scale, which will likely happen and accelerate over the next 2-3 years. Agentic AI PaaS solutions will likely include the following:

- Self-Service Conversational AI Agents: Sales, Marketing, and Customer Service

- Value-Based Care (VBC), Population Health Management, Care Management Prescriptive Analytics: Alerts, Care Management, Patient Scheduling

- Personal AI Assistants for Senior Executives: Performance Monitoring and Decision Support

- Manufacturing, Supply Chain, Clinical Trials, and Fraud Waste and Abuse (FWA): Process Monitoring & Exception Management

- Self-Service Coding for Automation and Agent Creation

The evolution of enterprise SaaS to enterprise AI PaaS over the next five years will reshape the future of enterprise software in healthcare, life sciences and every other industry.

IV. The Future of AI Platform-as-a-Service (AI PaaS)

The next significant disruption of the enterprise SaaS industry will be its reconfiguration on agentic AI platforms to enable process and workflow automation as well as decision support at scale. These will automate manual, repetitive, human-error-prone tasks, workflows, and processes initially—and eventually reconfigure many job descriptions and responsibilities.

Platform solutions like EHRs with ambient listening as an embedded feature/functionality, Enterprise Resource Planning (ERP), as well as solutions for Customer Relationship Management (CRM), Revenue Cycle Management (RCM), Supply Chain Management (SCM), Clinical Trial Management (CTM), R&D, Governance Risk and Compliance (GRC) are being/will be re-written for agentic AI to support.

1. AI Prescriptive Actioning 2. AI Automation (tasks, workflows, and processes) and eventually 3. Autonomous AI, as illustrated in figure below.

A visionary roadmap for the evolution of AI in Healthcare enabled by agentic AI/AI agents and its impact on the Enterprise SaaS Landscape over the next 5 years (2025-2030).

This future is happening as we speak with agentic AI solutions hitting the market. The transformation is underway. Where will you start yours? Read more about Lightbeam AI, or request a demo. Access my industry thought leadership portfolio at www.AndyDe.com and on LinkedIn.

#HIMSS25 #AIinHealthcare #MachineLearning #NLP #NLG #AIagents #AgenticAI #AIPaaS #AIaaS #MedicalRobotics #EntepriseSaaSDisruption #LightbeamAI